title: Expect p&t committees to demand more data.
abstract: High-profile drug withdrawals may cause formulary committees to view biologics and other 'breakthrough' therapies more skeptically. P&T members are likely to ask many more questions before approving such products.
authors: Scott
authors: S
authors: Kober